NCT07163624 - UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

March 22, 2025

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2025

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

UBT251 Injection 2.0 mg and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

UBT251 Injection 6.0 mg and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

Semaglutide Injection (Ozempic®)

Semaglutide Injection (Ozempic®) once weekly

Trial Locations (1)

The United Bio-Technology (Hengqin) Co., Ltd., Zhuhai

All Listed Sponsors

lead

The United Bio-Technology (Hengqin) Co., Ltd.

INDUSTRY